Lexington, MA-based Aldeyra Therapeutics, Inc. (ALDX - Free Report) is a clinical-stage biotechnology company, which focuses on the development of novel therapies for immune-mediated diseases.
The company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP) leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes and Scavenger Receptor A. The pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in phase III testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in phase II testing for COVID-19 and ovarian cancer.
Aldeyra beat earnings expectations by 29.17% in the last reported quarter. Over the trailing four quarters, it surpassed earnings estimates on three occasions, the average surprise being 8.45%.
Currently, Aldeyra has a Zacks Rank #3 (Hold).
Earnings: Aldeyra incurred a loss of 25 cents beating the Zacks Consensus Estimate of a loss of 34 cents.
Revenues: In the absence of a marketed product, Aldeyra is yet to generate any revenues.
Key Stats: Research and development expenses were $4.9, down 54.2% year-over-year. General and administrative expenses were $2.2 in the second quarter, down 29% on a yearly basis.
2020 Guidance: Aldeyra expects that its cash, cash equivalents and marketable securities as of June 30, 2020 will be able to fund its anticipated operating expenses and capital expenditure requirements at least through the end of 2022.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2021.
Click here for the 6 trades >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Lexington, MA-based Aldeyra Therapeutics, Inc. (ALDX - Free Report) is a clinical-stage biotechnology company, which focuses on the development of novel therapies for immune-mediated diseases.
The company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP) leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes and Scavenger Receptor A. The pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in phase III testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in phase II testing for COVID-19 and ovarian cancer.
Aldeyra beat earnings expectations by 29.17% in the last reported quarter. Over the trailing four quarters, it surpassed earnings estimates on three occasions, the average surprise being 8.45%.
Currently, Aldeyra has a Zacks Rank #3 (Hold).
Earnings: Aldeyra incurred a loss of 25 cents beating the Zacks Consensus Estimate of a loss of 34 cents.
Revenues: In the absence of a marketed product, Aldeyra is yet to generate any revenues.
Key Stats: Research and development expenses were $4.9, down 54.2% year-over-year. General and administrative expenses were $2.2 in the second quarter, down 29% on a yearly basis.
2020 Guidance: Aldeyra expects that its cash, cash equivalents and marketable securities as of June 30, 2020 will be able to fund its anticipated operating expenses and capital expenditure requirements at least through the end of 2022.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2021.
Click here for the 6 trades >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on ALDX - FREE